Skip to main content

This website is intended for US healthcare professionals only.

INGREZZA® (valbenazine) capsules

Patient-reported outcomes in tardive dyskinesia

KINECT-PRO Patient Reported Outcomes

KINECT-PRO™: A Landmark, Phase 4, Open-Label Study1

  • KINECT-PRO is the first study to evaluate TD impact and burden using multiple validated patient-reported outcome measures; data shown here are for one of these measures (Tardive Dyskinesia Impact Scale™)
  • This study was a phase 4, open-label, single-arm, interventional, prospective study of patients without use of a VMAT2 inhibitor within the last month.
  • Included 59 patients with schizophrenia, schizoaffective disorder, or mood disorder and at least mild TD*
  • Patients were started on 40 mg for 4 weeks, and adjustments were allowed up to the patients' highest tolerable dose (40, 60, or 80 mg) through Week 16. Stable dosing was encouraged in weeks 16 through 24.

*Measured by AIMS Item 8 (global severity) score ≥2.


The TD Impact Scale (TDIS) is the only PRO measure specifically designed for and validated in TD patients2

The TD Impact Scale (TDIS) is an 11-item questionnaire to evaluate how TD affects a patient’s daily functioning over the past 7 days. Each question is scored on a 5-point scale from 0 (no impact) to 4 (most impact), resulting in a score of 0 to 44.


Physical and social/emotional items
Physical and social/emotional items

Physical and social/emotional items
Physical and social/emotional items

Learn more about validation of the TD Impact Scale (TDIS)

GET THE REPRINT



Clinically meaningful reductions in TD impact were reported by patients on INGREZZA1

AS MEASURED BY THE TD IMPACT SCALE

Mean change in TD Impact Scale from baseline to Week 241

Mean change in Tardive Dyskinesia Impact Score (TDIS)
Mean change in Tardive Dyskinesia Impact Score (TDIS)

SIMPLE FROM THE START

Only INGREZZA offers a therapeutic dose from Day 13

EXPLORE DOSING

SEE REAL-WORLD RESULTS
WITH INGREZZA

View videos of real-world patients with TD treated with INGREZZA

WATCH CASE VIDEOS

INGREZZA CLINICAL
SAFETY DATA

INGREZZA was studied across a broad range of TD patients

VIEW SAFETY PROFILE

REFERENCES:

  1. Data on file. Neurocrine Biosciences, Inc.
  2. Farber RH, Stull DE, Witherspoon B, et al. The Tardive Dyskinesia Impact Scale (TDIS), a novel patient-reported outcome measure in tardive dyskinesia: development and psychometric validation. J Patient Rep Outcomes. 2024;8(1):2.
  3. INGREZZA [package insert]. San Diego, CA: Neurocrine Biosciences, Inc.
+Expand-Collapse

Important Safety Information

Depression and Suicidality in Patients with Huntington’s Disease: VMAT2 inhibitors, including INGREZZA, can increase the risk of depression and suicidal thoughts and

Important Information

INDICATION & USAGE

INGREZZA® (valbenazine) capsules and INGREZZA® SPRINKLE (valbenazine) capsules are indicated in adults for the treatment of tardive dyskinesia and for the treatment of chorea associated with Huntington’s disease.

IMPORTANT SAFETY INFORMATION

Depression and Suicidality in Patients with Huntington’s Disease: VMAT2 inhibitors, including INGREZZA and INGREZZA SPRINKLE, can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease. Balance the risks of depression and suicidality with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidal ideation, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidal ideation and behavior and instruct them to report behaviors of concern promptly to the treating physician. Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation, which are increased in frequency in patients with Huntington’s disease.